Photodynamic therapy in dermatology

Journal of the American Academy of Dermatology

Volumn 42, Issue 3, 2000, Pages 389-413

  Kalka, Katrin ^a   Merk, Hans ^b   Mukhtar, Hasan ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; BENZOPORPHYRIN DERIVATIVE; ETIOPURPURIN; HEMATOPORPHYRIN DERIVATIVE; HPPH 23; LUTETIUM TEXAPYRIN; PHOTOFRIN; PHOTOSENSITIZING AGENT; PHTHALOCYANINE; PORPHYRIN; PORPHYRIN DERIVATIVE; TALAPORFIN; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; BASAL CELL CARCINOMA; BOWEN DISEASE; DOSIMETRY; HUMAN; KAPOSI SARCOMA; LASER; LIGHT ABSORPTION; MELANOMA; MYCOSIS FUNGOIDES; NEUROTOXICITY; PAIN; PHOTOCHEMISTRY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PRURITUS; PSORIASIS; REVIEW; SKIN CANCER; SKIN METASTASIS; SQUAMOUS CELL CARCINOMA; TARGET CELL DESTRUCTION; TREATMENT INDICATION; VIRAL SKIN DISEASE;

EID: 0033925324     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (276)

1. Fitzpatrick TB, Pathak MA. Historical aspects of methoxsalen and other furocoumarins. J Invest Dermatol 1059:23:229-31.
2. Daniel MD, Hill JS. A history of photodynamic therapy. Aust N Z J Surg 1991;61:340-8.
3. Wilson BT, Mang T. Photodynamic therapy for cutaneous malignancies. Clin Dermatol 1995;13:91-6.
4. Von Tappeiner H, Jodlbauer A. Ueber die Wirkung der photodynamischen (fluorescierenden) Stoffe auf Protozoan und Enzyme. Dtsch Arch Klin Med 1904;80:427-87.
5. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905.
6. Raab O. Ueber die Wirkung fluoreszierenden Stoffe auf Infusorien. Z Biol 1900;39:524-6.
7. Von Tappeiner H, Jesionek A. Therapeutische Versuche mit fluorescierenden Stoffen. Munch Med Wochenschr 1903;47:2042-4.
8. Policard A. Etude sur les aspects offerts par des tumeurs experimentales examinées à la lumiere de Wood. CR Soc Biol 1924;91:1423-4.
9. Auler H, Banzer G. Untersuchungen ueber die Rolle der Porphyrine bei geschwulstkranken Menschen und Tieren. Z Krebsforsch 1942;53:65-8.
10. Figge FHJ, Weiland GS, Manganiello LOJ. Cancer detection and therapy: affinity of neoplastic, embryonic and traumatized tissues for porphyrins and metalloporphyrins. Proc Soc Exp Biol Med 1948;68:640-1.
11. Schwartz SK, Absolon K, Vermund H. Some relationships of porphyrins, X-rays and tumors. Univ Minn Med Bull 1955;27:7-13.
12. Kick G, Messer G, Plewig G. Historische Entwicklung der Photodynamischen Therapie. Hautarzt 1996;47:644-9.
13. Lipson RL, Baldes EJ, Olsen EM. The use of a derivative of hematoporphyrin in tumor detection. J Natl Cancer Inst 1961;26:1-2.
14. Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res 1978;38:2628-35.
15. Gomer CJ, Rucker N, Ferrario A, Wong S. Properties and application of photodynamic therapy. Radiat Res 1989;120:1-18.
16. Dougherty TJ. Photodynamic therapy. Photochem Photobiol 1993;58:895-900.
17. McCaughan JS Jr, Brown DG, Hawley PC. Photodynamic therapy: an eight year experience. In: Henderson BW, Dougherty TJ, editors. Photodynamic therapy: basic principle and clinical application. New York: Marcel Dekker; 1992. p. 323-31.
18. Pass HI, Delaney TF. Innovative photodynamic therapy at the National Cancer Institute: intraoperative intracavity treatment. In: Henderson BW, Dougherty TJ, editors. Photodynamic therapy: basic principle and clinical application. New York: Marcel Dekker; 1992. p. 287-301.
19. Rowe PM. Photodynamic therapy begins to shine. Lancet 1998;351:1496.
20. Saito T, Hayashi J, Sato H, Kawabe H, Aizawa K. Scanning electron microscopic analysis of acute photodynamic therapy for atherosclerotic plaques of rabbit aorta using a pheophorbide derivative. J Clin Laser Med Surg 1996;14:1-6.
21. Ben-Hur E, Oetjen J, Horowitz B. Silicon phthalocyanine Pc4 and red light causes apoptosis in HIV-infected cells. Photochem Photobiol 1997;65:456-60.
22. Ratkay LG, Chowdhary RK, Iamaroon A, Richter AM, Neyndorff HC, Keystone EC, et al. Amelioration of antigen-induced arthritis in rabbits by induction of apoptosis of inflammatory cells with local application of transdermal photodynamic therapy. Arthritis Rheum 1998;41:525-43.
23. Hendrich C, Siebert WE. Photodynamic therapy for rheumatoid arthritis? Lasers Surg Med 1997;21:359-64.
24. Lui H, Anderson RR. Photodynamic therapy in dermatology: recent developments. Dermatol Clin 1993;11:1-13.
25. McCaughan JS, Guy JT, Hicks W, Laufman L, Nims TA, Walker J. Photodynamic therapy for cutaneous and subcutaneous malignant neoplasms. Arch Surg 1989;124:211-6.
26. Bissonnette R, Lui H. Current status of photodynamic therapy in dermatology. Dermatol Clin 1997;15:507-19.
27. Ash DV, Brown SB. New drugs and future developments in photodynamic therapy. Eur J Cancer 1993;29A:1781-3.
28. Moan J. Properties for optimal PDT sensitizers. J Photochem Photobiol 1990;5:521-4.
29. Moan J, Peng Q, Evensen JF, Berg K, Western A, Rimington C. Photosensitizing efficiencies, tumor- and cellular uptake of different photosensitizing drugs relevant for photodynamic therapy of cancer. Photochem Photobiol 1987;46:713-21.
30. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992;55:145-57.
31. Evensen JF. The use of porphyrins and non-ionizing radiation for treatment of cancer. Acta Oncol 1995;8:1103-10.
32. Bohmer RM, Morstyn G. Uptake of hematoporphyrin derivative by normal and malignant cells: effect of serum, pH, temperature, and cell size. Cancer Res 1985;45:5328-34.
33. Van Hillegersberg R, Kort WJ, Wilson JHP. Current status of photodynamic therapy in oncology. Drugs 1994;48:510-27.
34. Moan J, Christensen T, Jacobsen PB. Porphyrin-sensitized photoinactivation of cells in vitro. In: Doiron D, Gomer CJ, editors. Porphyrin localization and treatment of tumors. Progress in Clinical and Biological Research Series; vol 170. New York: Alan R Liss Inc; 1984. p. 419-42.
35. Mang TS, Dougherty TJ, Potter WR, Boyle DG, Somer S, Moan J. Photobleaching of porphyrins used in photodynamic therapy and implications for therapy. Photochem Photobiol 1987;45:501-6.
36. Driver I, Lowdell CP, Ash DV. In vivo measurements of the optical interaction coefficients of human tumours. Phys Med Biol 1991;36:805-13.
37. Wilson BC. The physics of photodynamic therapy. Phys Med Biol 1986;31:327-60.
38. Frazier CC. Photodynamic therapy in dermatology. Int J Dermatol 1996;35:312-6.
39. Wolf P. Photodynamische Therapie (PDT). Hautarzt 1997;48: 137-48.
40. Cannon JB. Pharmaceutics and drug delivery aspects of heme and porphyrin therapy. J Pharm Sci 1993;82:435-46.
41. Lui H. Photodynamic therapy in dermatology. Arch Dermatol 1992;128:1631-6.
42. 14C hematoporphyrin derivative distribution in normal and malignant tissue. Cancer Res 1979;39:146-51.
43. Bugelski DA, Porter CW, Dougherty TJ. Autoradiographic distribution of hematoporphyrin derivative in normal and tumour tissue of the mouse. Cancer Res 1981;41:4606-12.
44. Woodburn KW, Stylli S, Hill JS, Kaye AH, Reiss JA, Phillips DR. Evaluation of tumour and tissue distribution of porphyrins for use in photodynamic therapy. Br J Cancer 1992;65:321-8.
45. Dougherty TJ, Potter WR, Weishaupt KR. The structure of the active component of hematoporphyrin derivative. Prog Clin Biol Res 1984;170:301-14.
46. Dougherty TJ. Studies on the structure of porphyrins contained in Photofrin II. Photochem Photobiol 1987;46:569-73.
47. Reynolds T. Photodynamic therapy expands its horizons. J Natl Cancer Inst 1997;89:112-4.
48. Ochsner M. Photodynamic therapy: the clinical perspective. Arzneim Forsch Drug Res 1997;47:1185-94.
49. Soret JL. Recherches sur l'absorption des rayons ultra violets par diverses substances. Arch Sci Phys Nat 1883;10:430-85.
50. Stables GI, Ash DV. Photodynamic therapy. Cancer Treat Rev 1995;21:311-23.
51. Gomer CJ. Preclinical examination of first and second-generation photosensitizers used in photodynamic therapy. Photochem Photobiol 1991;54:1093-107.
52. McCullough JL, Weinstein GD, Lemus LL, Rampone W, Jenkins JJ. Development of a topical hematoporphyrin derivative formulation: characterization of photosensitizing effects in vivo. J Invest Dermatol 1983;81:528-32.
53. Meffert VH, Pres H, Diezel W, Sonnichsen N. Anti-psoriasis and phototoxic effect of a hematoporphyrin derivative following topical administration and irradiation with visible light. Dermatol Monatsschr 1989;175:28-34.
54. Pres H, Meffert H, Sonnichsen N. Photodynamic therapy of psoriasis palmaris et plantaris using a topically applied hematoporphyrin derivative and visible light. Dermatol Monatsschr 1989;175:745-50.
55. Steiner RA, Tromberg BJ, Wyss P, Krasieva T, Chandanani N, McCullough J, et al. Rat reproductive performance following photodynamic therapy with topically administered Photofrin. Hum Reprod 1995;10:227-33.
56. Peng Q, Warloe T, Berg C, Moan J, Kongshaug M, Giercksky KE, et al. 5-Aminolevulinic acid-based photodynamic therapy: clinical research and future challenges. Cancer 1997;79:2282-308.
57. Peng Q, Berg K, Moan J, Kongsaug M, Nesland JM. 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol 1997;65: 235-51.
58. Malik Z, Lugaci H. Destruction of erythroleukaemic cells by photoactivation of endogenous porphyrins. Br J Cancer 1987;56:589-95.
59. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990;14:275-92.
60. Bermudez Moretti M, Correa Garcia SR, Stella C, Ramos EH, Battle A. Delta-aminolevulinic acid transport in saccharomyces cerevisiae. Int J Biochem 1993;25:1917-24.
61. Kalka K, Fritsch C, Ruzicka T, Goerz G, Eckel J. δ-Aminolevulinic acid accumulates intracellularly mainly by transport mechanism and not via passive diffusion. Acta Haematol 1998;Suppl 1:101.
62. Ortel B, Tanew A, Honigsmann H. Lethal photosensitization by endogenous porphyrins of PAM cells: modification by desferrioxamine. J Photochem Photobiol B 1993;17:273-8.
63. Peng Q, Moan J, Jani V, Nesland JM. Effect of desferrioxamine on production of ALA-induced protoporphyrin IX in normal mouse skin. Proc SPIE 1996;2625:51-7.
64. Malik Z, Kostenich G, Roitman L, Ehrenberg B, Orenstein A. Topical application of 5-aminolevulinic acid, DMSO and EDTA: protoporphyrin IX accumulation in skin and tumors of mice. J Photochem Photobiol B 1995;28:213-8.
65. Warloe T, Peng Q, Heyerdahl J, Moan J, Steen B, Giercksky KE. Photodynamic therapy with 5-aminolevulinic acid induced porphyrins and DMSO/EDTA for basal cell carcinoma. Proc SPIE 1995;2371:226-35.
66. Kreimeier-Birnbaum M. Modified porphyrins, chlorins, phthalocyanines and purpurins: second-generation photosensitizers for photodynamic therapy. Semin Hematol 1989;26:157-73.
67. Santoro O, Bandieramonte G, Melloni E, Marchesini R, Zunino F, Lepera P, et al. Photodynamic therapy by topical mesotetraphenylporphinesulfonate tetrasodium salt administration in superficial basal cell carcinomas. Cancer Res 1990;50:4501-3.
68. Pass HI. Photodynamic therapy in oncology: mechanisms and clinical use. J Natl Cancer Inst 1993;85:443-56.
69. 4 and its relation to photodynamic therapy. Photochem Photobiol 1987;46:801-7.
70. Evensen JF. Distribution of tetraphenylporphine sulphonate in mice bearing Lewis lung carcinoma. In: Jori G, Perria C, editors. Photodynamic therapy of tumors and other diseases. Padova: Libreria Progetto; 1985. p. 215-8.
71. Kessel D, Thompson P, Saatio K, Nantwi KD. Tumor localization and photosensitization by sulfonated derivatives of tetraphenylporphine. Photochem Photobiol 1987;45:787-90.
72. Lui H, Anderson RR. Photodynamic therapy in dermatology: shedding a different light on skin disease. Arch Dermatol 1992;128:1631-6.
73. Ben-Hur E, Rosenthal I. The phthalocyanines: a new class of mammalian photosensitizers with potential for cancer phototherapy. Int J Radiat Biol 1985;47:145-7.
74. Canti G, Franco P, Marelli O, Cubeddu R, Taroni P, Ramponi R, et al. Comparative study of the therapeutic effect of photoactivated hematoporphyrin derivative and aluminium disulfonated phthalocyanines on tumor bearing mice. Cancer Lett 1990; 53:123-7.
75. Anderson CY, Freye K, Tubesing KA, Li Y-S, Kenney ME, Mukhtar H, et al. A comparative analysis of silicon phthalocyanine photosensitizers for in vivo photodynamic therapy of RIF-1 tumor in C3H mice. Photochem Photobiol 1998;67:332-6.
76. Colussi VC, Feyes DK, Li Y-S, Mulvihill J, Kenney ME, Elmets CA, et al. Phthalocyanine (Pc4) photodynamic therapy (PDT) of human OVCAR-3 tumors. Photochem Photobiol 1998;67 (Suppl):25S.
77. Spikes JD. Phthalocyanines as photosensitizers in biological systems and for the photodynamic therapy of tumors. Photochem Photobiol 1986;43:691-9.
78. Oleinick NL, Antunez AR, Clay ME, Rihter BD, Kenney ME. New phthalocyanine photosensitizers for photodynamic therapy. Photochem Photobiol 1993;57:242-7.
79. Rosenthal I. Phthalocyanines as photodynamic sensitizers. Photochem Photobiol 1991;53:859-70.
80. Tralau CJ, Barr H, Sanderman R, Barton T, Lewin MR, Bown SG. Aluminium sulfonated phthalocyanine distribution in rodent tumors of the colon, brain and pancreas. Photochem Photobiol 1987;46:777-81.
81. Agarwal R, Athar M, Elmets C, Bickers DR, Mukhtar H. Photodynamic therapy of chemically- and ultraviolet B radiation-induced murine skin papillomas by chloroaluminium phthalocyanine tetrasulfonate. Photochem Photobiol 1992;56: 43-50.
82. Sokolov W, Chissov VI, Filonenko EV, Yakubovskya RI, Sukhin DG, Galpern MG, et al. First clinical results with a new drug for PDT. In: Brault D, Jori G, Moan J, Ehrenberg B, editors. Photodynamic therapy of cancer II. Proc SPIE 1995;2325:364-6.
83. Sokolov VV, Chissov VI, Yakubovskya RI, Aristarkhova EI, Filonenko EV, Belous TA, et al. Photodynamic therapy (PDT) of malignant tumors by photosensitizer Photosens: results of 45 clinical cases. In: Ehrenberg B, Jori G, Moan J, editors: Photochemotherapy: photodynamic therapy and other modalities. Proc SPIE 1996;2625:281-7.
84. Zaidi SIA, Agarwal R, Eichler G, Rihter BD, Kenney ME, Mukhtar H. Photodynamic effects of new silicon phthalocyanines: in vitro studies utilizing rat hepatic microsomes and human erythrocyte ghosts as model membrane sources. Photochem Photobiol 1993;58:204-10.
85. Agarwal R, Korman NJ, Mohan RR, Feyes DK, Jawed S, Zaim MT, et al. Apoptosis is an early event during phthalocyanine photodynamic therapy-induced ablation of chemically induced squamous papillomas in mouse skin. Photochem Photobiol 1996;63:547-52.
86. Zaidi SIA, Oleinick NL, Zaim MT, Mukhtar H. Apoptosis during photodynamic therapy-induced ablation of RIF-1 tumors in C3H mice:electron microscopic, histopathologic and biochemical evidence. Photochem Photobiol 1993;58:771-6.
87. Young C, Mukhtar H, Tubesing K, Mulvihill J, Elmets CA. Pc4 PDT cutaneous photosensitivity and tumor regression occur through disparate mechanisms. Photochem Photobiol 1994;59(Suppl):32-3S.
88. Anderson CY, Hrabovsky S, McKinley Y, Tubesing KA, Tang HP, Dunbar R, et al. Phthalocyanine photodynamic therapy: disparate effects of pharmacologic inhibitors on cutaneous photosensitivity and on tumor regression. Photochem Photobiol 1997;65:895-901.
89. Richter AM, Waterfield E, Jain AK, Canaan AJ, Allison BA, Levy JG. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumor tissue in a mouse tumor model. Photochem Photobiol 1993;57:1000-6.
90. Levy JG. Photosensitizers in photodynamic therapy. Semin Oncol 1994;21:4-10.
91. Spikes JD. Chlorins as photosensitizers in biology and medicine. J Photochem Photobiol B 1990;6:259-74.
92. 6 (Npe6) for the treatment of cutaneous disease: a phase I clinical study. Clin Cancer Res 1998;4:2741-6.
93. Nelson JS, Roberts WG, Berns MW. In vivo studies on the utilization of mono-L-aspartyl chlorin (Npe6) for photodynamic therapy. Cancer Res 1987;47:4681-5.
94. 6 in a mouse tumor model. Cancer Res 1990;50:3985-90.
95. Wilson BD, Mang T. Photodynamic therapy for cutaneous malignancies. Clin Dermatol 1995;13:91-6.
96. Razum NJ, Snyder AB, Doiron DR. SnET2: clinical update. In: Dougherty TJ, editor. Optical methods for tumor treatment and detection: mechanisms and techniques in photodynamic therapy V. Proc SPIE 1996;2675:43-6.
97. Morgan AR, Garbo GM, Keck RW, Selman SH. New photosensitizers for photodynamic therapy: combined effect of metallopurpurin derivatives and light on transplantable tumors. Cancer Res 1988;48:194-8.
98. Garbo GM. Purpurins and benzochlorins as sensitizers for photodynamic therapy. J Photochem Photobiol B 1996;34:109-16.
99. Young SW, Woodburn KW, Wright M, Mody TD, Fan Q, Sessler JL, et al. Lutetium texaphyrin (PCI-0123): a near-infrared, water-soluble photosensitizer. Photochem Photobiol 1996;63:892-7.
100. Woodburn KW, Fan Q, Kessel D, Wright M, Mody TD, Hemmi G, et al. Phototherapy of cancer and atheromatous plaque with texaphyrins. J Clin Laser Med Surg 1996;14:343-8.
101. Renschler MF, Yuen A, Panella TJ, Wieman TJ, Julius C, Panjehpour M, et al. Photodynamic therapy trials with lutetium texaphyrin PCI-0123 (Lu-Tex). Photochem Photobiol 1997; 65(Suppl):47S.
102. Magne ML, Rodriguez CO, Autry SA, Edwards BF, Theon AP, Madewell BR. Photodynamic therapy of facial squamous cell carcinoma in cats using a new photosensitizer. Lasers Surg Med 1997;20:202-9.
103. Diwu Z, Lown W. Phototherapeutic potential of alternative photosensitizers to porphyrins. Pharmacol Ther 1994;63:1-35.
104. Kessel D, Smith KM, Pandey RK, Shiau F-Y, Henderson B. Photosensitization with bacteriochlorins. Photochem Photobiol 1993;58:200-3.
105. Kessel D, Woodburn K, Henderson BW, Chang CK. Sites of photodamage in vivo and in vitro by a cationic porphyrin. Photochem Photobiol 1995;62:875-81.
106. Nelson JS, Liaw LH, Lahlum RA, Cooper PL, Berns MW. Use of multiple photosensitizers and wavelengths during photodynamic therapy: a new approach to enhance tumor eradication. J Natl Cancer Inst 1990;82:868-73.
107. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992;55:145-57.
108. Dougherty TJ, Marcus SL. Photodynamic therapy. Eur J Cancer 1992;28A:1734-42.
109. Fisher AMR, Murphree AL, Gomer CJ. Clinical and preclinical photodynamic therapy. Lasers Surg Med 1995;17:2-31.
110. Szeimies RM, Hein R, Baumler W, Heine A, Landthaler M. A possible new incoherent lamp for photodynamic treatment of superficial skin lesions. Acta Derm Venereol (Stockh) 1994;74: 117-9.
111. Roberts DJH, Cairnduff F. Photodynamic therapy of primary skin cancer: a review. Br J Plast Surg 1995;48:360-70.
112. Whitehurst C, Byrne K, Moore JV. Development of an alternative light source to lasers for photodynamic therapy: 1. Comparative in vitro dose response characteristics. Lasers Med Sci 1993;8:259-67.
113. Whitehurst C, Byrne KT, Morton C, Moore JV. Performance of a nonlaser light source for photodynamic therapy. Proc SPIE 1995;2371:482-8.
114. Karrer S, Szeimies RM, Hohenleutner U, Heine A, Landthaler M. Unilateral localized basaliomatosis: treatment with topical photodynamic therapy after application of 5-aminolevulinic acid. Dermatology 1995;190:218-22.
115. McCaughan L. Lasers in photodynamic therapy. Nurs Clin North Am 1990;25:725-38.
116. Cowled PA, Grace R, Forbes IJ. Comparison of the efficacy of pulsed and continuous wave red laser light in induction of photocytotoxicity by hematoporphyrin derivative. Photochem Photobiol 1984;39:115-7.
117. McKenzie AL, Carruth JAS. A comparison of gold vapour and dye lasers for photodynamic therapy. Lasers Med Sci 1986;1: 117-20.
118. Shikowitz MJ. Comparison of pulsed and continuous wave light in photodynamic therapy of papillomas: an experimental study. Laryngoscope 1992;102:300-10.
119. Wieman TJ, Fingar VH. Photodynamic therapy. Surg Clin North Am 1992;72:609-22.
120. Gomer CJ, Ferrario A, Hayashi N, Rucker N, Szirth B, Murphree AL. Molecular, cellular and tissue responses following photodynamic therapy. Lasers Surg Med 1988;8:450-63.
121. Stern SJ, Craig J, Flock S, Montague D, Waner M, Jacques S. Tumor specific response to photodynamic therapy. Lasers Surg Med 1993;13:434-9.
122. Manyak MJ, Russo A, Smith PD, Glatstein E. Photodynamic therapy. J Clin Oncol 1988;6:380-91.
123. Lin C-W. Photodynamic therapy of malignant tumors: recent developments. Cancer Cells 1991;3:437-44.
124. Moan J. On the diffusion length of singlet oxygen in cells and tissues. J Photochem Photobiol 1990;343-4.
125. Moan J, Christensen T. Cellular uptake and photodynamic effect of hematoporphyrin. Photobiochem Photobiophys 1981;2:291-9.
126. Volden G, Christensen T, Moan J. Photodynamic membrane damage of hematoporphyrin-derivative-treated NHIK 3025 cells in vitro. Photochem Photobiophys 1981;3:105.
127. Kessel D. Photosensitization with derivatives of hematoporphyrin. Int J Rad Biol 1986;49:901-7.
128. Kessel D. Sites of photosensitization by derivatives of hematoporphyrin. Photochem Photobiol 1986;44:489-93.
129. Hilf R, Smail DB, Murant RS, Leakay PB, Gibson SL. Hematoporphyrin derivative induced photosensitivity of mitochondrial succinate dehydrogenase and selected cytosolic enzymes of R3230 AC mammary adenocarcinomas of rats. Cancer Res 1984;44:1483-8.
130. Jori G, Spikes JD. Photochemistry of porphyrins. In: Smith KC, editor. Topics in photomedicine. New York: Plenum; 1984. p. 183-318.
131. Evensen JF, Malik Z, Moan J. Ultrastructural changes in the nuclei of human carcinoma cells after photodynamic treatment with hematoporphyrin derivative and with tetrasodium-meso-tetra- (4-sulphonatophenyl) porphine. Lasers Med Sci 1988;3:195-206.
132. Evensen JF, Moan J. Photodynamic action and chromosomal damage: a comparison of haematoporphyrin derivative (HpD) and light with x-irradiation. Br J Cancer 1982;45:456-65.
133. Gomer CJ, Rucker N, Banerjee A, Benedict WF. Comparison of mutagenicity and induction od sister chromatid exchange in Chinese hamster cells exposed to haematoporphyrin derivative, ionizing radiation or ultraviolet radiation. Cancer Res 1983;43:2622-7.
134. Gomer CJ, Rucker N, Murphree AL. Transformation and mutagenic potential of porphyrin photodynamic therapy in mammalian cells. Int J Radiat Biol 1988;53:651-9.
135. Gomer CJ, Rucker N, Murphree AL. Differential cell photosensitivity following porphyrin photodynamic therapy. Cancer Res 1988;48:4539-42.
136. Gomer CJ, Ferrario A, Rucker N, Wong S, Lee AS. Glucose-regulated protein induction and cellular resistance to oxidative stress mediated by porphyrin photosensitization. Cancer Res 1991;51:6574-6579.
137. Gomer CJ, Luna M, Ferrario A, Rucker N. Increased transcription and translation of heme oxygenase in Chinese hamster fibroblasts following photodynamic stress or Photofrin II incubation. Photochem Photobiol 1991;53:275-9.
138. Fisher AMR, Ferrario A, Gomer CJ. Adriamycin resistance in Chinese hamster fibroblasts following oxidative stress induced by photodynamic therapy. Photochem Photobiol 1993;58:581-8.
139. Luna MC, Wong S, Gomer CJ. Photodynamic therapy mediated induction of early response genes. Cancer Res 1994;53:1374-80.
140. Agarwal ML, Clay ME, Harvey EJ, Evans HH, Antunez AR, Oleinick NL. Photodynamic therapy induces rapid cell death by apoptosis in L5178Y mouse lymphoma cells. Cancer Res 1991;51:5993-6.
141. Ahmad N, Feyes DK, Agarwal R, Mukhtar H. Photodynamic therapy results in induction of WAF1/CIP1/P21 leading to cell cycle arrest and apoptosis. Proc Natl Acad Sci 1998;95:6977-82.
142. Kalka K, Ahmad N, Feyes DKF, Mukhtar H. P53-dependent induction of WAF1/p21 during PDT-mediated apoptosis and ablation of mouse skin tumors. Photochem Photobiol 1999; 69(Suppl):7S.
143. McGovern VJ. The mechanism of photosensitivity. Arch Dermatol 1961;83:94-105.
144. Klausner JM, Paterson IS, Kobzik L, Valeri CR, Shepro D, Hechtman HB. Oxygen free radicals mediate ischemia-induced lung injury. Surgery 1989;105:192-9.
145. Doukas J, Hechtman HB, Shepro D. Vasoactive amines and eicosanoids interactively regulate both polymorphonuclear leukocyte diapedesis and albumin permeability in vitro. Microvasc Res 1989;37:125-37.
146. Korbelik M. Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg 1996;14:329-34.
147. Fingar VH. Vascular effects of photodynamic therapy. J Clin Laser Med Surg 1996;14:323-8.
148. Krosl G, Korbelik M, Dougherty GJ. Induction of immune cell infiltration into murine SCCVII tumor by photofrin-based photodynamic therapy. Br J Cancer 1995;71:549-55.
149. Gollnick SO, Liu X, Owczarczak B, Musser DA, Henderson BW. Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res 1997;57: 3904-9.
150. Canti G, Lattuada D, Nicolin A, Taroni P, Valentini G, Cubeddu G. Antitumor immunity induced by photodynamic therapy with aluminium phthalocyanine and laser light. Anticancer Drugs 1994;5:443-7.
151. Pogrebniak H, Matthews W, Black C, Russo A, Mitchell B, Smith P, et al. Targeted phototherapy with sensitizer-monoclonal antibody and light. Surg Oncol 1993;2:31-42.
152. Goff BA, Hermanto U, Rumbaugh J, Blake J, Bamberg M, Hasan T. Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model. Br J Cancer 1994;70:474-80.
153. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992;14:275-92.
154. Wolf P, Rieger E, Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid: an alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas? J Am Acad Dermatol 1993;28:17-21.
155. Morton CA, Whitehurst C, Moseley H, Moore JV, MacKie RM. Development of an alternative light source to lasers for photodynamic therapy. 1. Clinical evaluation in the treatment of premalignant and non-melanoma skin cancer. Lasers Med Sci 1995;10:165-71.
156. Fijan S, Hoenigsmann H, Ortel B. Photodynamic therapy of epithelial skin tumors using delta-aminolevulinic acid and desferrioxamine. Br J Dermatol 1995;133:282-8.
157. Calzavara-Pinton PG. Repetitive photodynamic therapy with topical delta-aminolevulinic acid as an appropriate approach to the routine treatment of superficial nonmelanoma skin tumors. J Photochem Photobiol B 1995;29:53-7.
158. Jeffes EW, McCullough JL, Weinstein GD, Fergin PE, Nelson JS, Shull TF, et al. Photodynamic therapy of actinic keratosis with topical 5-aminolevulinic acid. Arch Dermatol 1997;133:727-32.
159. Olsen EA, Abernethy L, Kulp-Shorten C, Callen JP, Glazer SD, Huntley A, et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol 1991;24:738-743.
160. Lawrence N, Cox SE, Cockerell CJ, Freeman RG, Cruz PD. A comparison of the efficacy and safety of Jessner's solution and 35% trichloric acid vs 5% fluorouracil in the treatment of widespread facial actinic keratoses. Arch Dermatol 1995;131:176-81.
161. Lubritz RR, Smolewski SS. Cryosurgery cure rate of actinic keratoses. J Am Acad Dermatol 1982;7:631-2.
162. Robinson PJ, Carruth JAS, Fairris GM. Photodynamic therapy: a better treatment for widespread Bowen's disease. Br J Dermatol 1988;119:59-61.
163. Buchanan RB, Carruth JAS, McKenzie AL, Williams SR. Photodynamic therapy in the treatment of malignant tumors of the skin and head and neck. Eur J Surg Oncol 1989;15:400-6.
164. Waldow SM, Lobraico RV, Kohler IK, Wallk S, Fritts HT. Photodynamic therapy for treatment of malignant cutaneous lesions. Lasers Surg Med 1987;7:451-6.
165. Jones CM, Mang T, Cooper M, Wilson BD, Stoll HL Jr. Photodynamic therapy in the treatment of Bowen's disease. J Am Acad Dermatol 1992;27:979-82.
166. Petrelli NJ, Cebollero JA, Rodriguez-Bigas M, Mang T. Photodynamic therapy in the management of neoplasms of the perianal skin. Arch Surg 1992;127:1436-8.
167. Cairnduff F, Stringer MR, Hudson EJ, Ash DV, Brown SB. Superficial photodynamic therapy with topical 5-aminolevulinic acid for superficial primary and secondary skin cancer. Br J Cancer 1994;69:605-8.
168. Svanberg K, Andersson T, Killander D, Wang I, Stenram U, Andersson-Engels S, et al. Photodynamic therapy of nonmelanoma malignant tumours of the skin using topical d-aminolevulinic acid sensitization and laser irradiation. Br J Dermatol 1994;130:743-51.
169. Wennberg AM, Lindholm L-E, Alpsten M, Larko O. Treatment of superficial basal cell carcinomas using topically applied delta-aminolevulinic acid and a filtered xenon lamp. Arch Dermatol Res 1996;288:561-4.
170. Morton CA, Whitehurst C, Moseley H, McColl HM, Moore JV, MacKie RM. Comparison of photodynamic therapy with cryotherapy in the treatment of Bowen's disease. Br J Dermatol 1996;135:766-71.
171. Pennington DG, Waner M, Knox A. Photodynamic therapy for multiple skin cancers. Plast Reconstr Surg 1988;82:1067-71.
172. Wilson BD, Mang TS, Stoll H, Jones C, Cooper M, Dougherty TJ. Photodynamic therapy for the treatment of basal cell carcinoma. Arch Dermatol 1992;128:1597-601.
173. Keller GS, Razum NJ, Doiron DR. Photodynamic therapy for nonmelanoma skin cancer. Facial Plast Surg 1989;6:180-4.
174. Warloe T, Peng Q, Moan J, Qvist HL, Giercksky KE. Photochemotherapy of multiple basal cell carcinoma with endogenous porphyrins induced by topical application of 5-aminolevulinic acid. In: Spinelli P, Fante MD, Marchesini R. Photodynamic therapy and biomedical lasers. Amsterdam: Elsevier Science; 1992. p. 449-53.
175. Svanberg K, Andersson T, Killander D. Photodynamic therapy of human skin malignancies and laser-induced fluorescence diagnostics utilizing Photofrin and delta-aminolevulinic acid. In: Spinelli P, Fante MD, Marchesini R. Photodynamic therapy and biomedical lasers. Amsterdam: Elsevier Science; 1992. p. 436-40.
176. Orenstein A, Kostenich G, Tsur H, Roitman L, Ehrenberg B, Malik Z. Photodynamic therapy of human skin tumors using topical application of 5-aminolevulinic acid, DMSO and EDTA. In: Brault D, Jori G, Moan J, Ehren berg B. Photodynamic therapy of cancer II. Proc SPIE 1995;2325:100-5.
177. Lui H, Salasche S, Ariz T, Kollias N, Wimberly J, Flotte T, et al. Photodynamic therapy of nonmelanoma skin cancer with topical aminolevulinic acid: a clinical and histologic study. Arch Dermatol 1995;131:737-8.
178. Martin A, Tope WD, Grevelink JM, Starr JC, Fewkes JL, Flotte TJ, et al. Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment. Arch Dermatol Res 1995;287:665-74.
179. Heinritz H, Benzel W, Sroka R, Iro H. Photodynamic therapy of superficial skin tumors following local application of delta-aminolaevulinic acid. Adv Otorhinolaryngol 1995;49:48-52.
180. Peng Q, Warloe T, Moan J, Heyerdahl H, Steen HB, Nesland JM, et al. Distribution of 5-aminolevulinic acid-induced porphyrins in noduloulcerative basal cell carcinoma. Photochem Photobiol 1995;62:906-13.
181. Morton CA, MacKie RM, Whitehurst C, Moore JV, McColl JH. Photodynamic therapy for basal cell carcinoma: effect of tumor thickness and duration of photosensitizer application on response. Arch Dermatol 1998;134:248-9.
182. Szeimies RM, Sassy T, Landthaler M. Penetration potency of topical applied α-aminolevulinic acid for photodynamic therapy of basal cell carcinoma. Photochem Photobiol 1994;59:73-6.
183. Tosca AD, Balas CJ, Stefanidou MP, Katsantonis JC, Georgiou SK, Tzardi MN. Photodynamic treatment of skin malignancies with aminolevulinic acid: emphasis on anatomical observations and in vivo erythema visual assessment. Dermatol Surg 1996;22: 929-34.
184. Tope WD, Kollias N, Martin A, Starr JC, Fewkes JL, Grevelink JM, et al. Oral delta-aminolevulinic acid induces full-thickness protoporphyrin IX fluorescence in basal cell carcinoma. Lasers Surg Med Suppl 1995;7:40.
185. Fink-Puches R, Wolf P, Kerl H. Photodynamic therapy of superficial basal cell carcinoma by instillation of aminolevulinic acid and irradiation with visible light. Arch Dermatol 1997;133: 1494-5.
186. Tse DT, Kersten RC, Anderson RL. Hematoporphyrin derivative photoradiation therapy in managing nevoid basal-cell carcinoma syndrome. Arch Ophthalmol 1984;102:990-4.
187. Rifkin R, Reed B, Hetzel F, Chen K. Photodynamic therapy using SnET2 for basal cell nevus syndrome: a case report. Clin Ther 1997;19:639-41.
188. Rowe DE, Carrol RJ, Day CL Jr. Long-term recurrence rates in previously untreated (primary) basal cell carcinoma: implications for patient follow-up. J Dermatol Surg Oncol 1989;15: 315-28.
189. Gregory RO, Goldman L. Application of photodynamic therapy in plastic surgery. Lasers Surg Med 1986;6:62-6.
190. Wolf P, Kerl H. Photodynamic therapy in a patient with xeroderma pigmentosum. Lancet 1991;337:1613-4.
191. Dougherty TJ. Photoradiation therapy for cutaneous and subcutaneous malignancies. J Invest Dermatol 1981;77:122-4.
192. Hebeda KM, Huizing MT, Brouwer PA, van der Meulen FW, Hulsebosch HJ, Reiss P et al. Photodynamic therapy in AIDS-related cutaneous Kaposi's sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10:61-70.
193. Schweitzer VG. Photodynamic therapy for treatment of head and neck cancer. Otolaryngol Head Neck Surg 1990;102:225-32.
194. Biel MA. Photodynamic therapy and the treatment of neoplastic diseases of the head and neck; an update. In: SPIE Optical Methods for Tumor Treatment and Detection. 1994;2133:39-52.
195. Dougherty TJ, Oseroff AR, Wilson BD, Jones C, Dozier S, Conti C, et al. An update of Photofrin-photodynamic therapy (PDT) for cutaneous tumors. Lasers Surg Med Suppl 1996;8:26.
196. Grekin RC, Berger T, Whitfield M, Toro J. Tin ethyl etiopurpurin (SnET2): phase I/II clinical results for the treatment of AIDS-related cutaneous Kaposi's sarcomas at the University of California, San Francisco. Lasers Surg Med Suppl 1995;7:44.
197. Wilson BD, Bernstein Z, Sommer C, Brooks J, Dougherty TJ, Mang T, et al. Photodynamic therapy for the treatment of Kaposi's sarcoma: a comparison study utilizing Photofrin and tin ethylethiopurpurin. Lasers Surg Med Suppl 1995;7:45.
198. Gill PS, Rarick M, McCutchan JA, Slater L, Parker B, Muchmore E, et al. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. Am J Med 1991;90:427-33.
199. Forbes IJ, Cowled PA, Leong AS-Y, Ward A, Black RB, Blake AJ, et al. Phototherapy of human tumours using haemotoporphyrin derivative. Med J Aust 1980;2:489-93.
200. Boehncke W-H, Koenig K, Rueck A, Kaufmann R, Sterry W. In vitro and in vivo effects of photodynamic therapy in cutaneous T cell lymphoma. Acta Derm Venereol (Stockh) 1994;74:201-5.
201. Wolf P, Fink-Puches R, Cerroni L, Kerl H. Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolevulinic acid. J Am Acad Dermatol 1994;31:678-80.
202. Shanler SD, Wan W, Whitaker JE, Mang TS, Jones C, Wilson BD et al. Photodynamic therapy with topical d-aminolevulinic acid for treatment of cutaneous carcinomas and cutaneous T cell lymphoma. J Invest Dermatol 1993;100:602.
203. Schoenfeld N, Mamet R, Nordenberg Y, Shafran M, Babushkin T, Malik Z. Protoporphyrin biosynthesis in melanoma B16 cells stimulated by 5-aminolevulinic acid and chemical inducers: characterization of photodynamic inactivation. Int J Cancer 1994;56:106-12.
204. Favilla I, Favilla ML, Gosbell AD, Barry WR, Ellims P, Hill JS, et al. Photodynamic therapy: a 5-year study of its effectiveness in the treatment of posterior uveal melanoma, and evaluation of haematoporphyrin uptake and photocytotoxicity of melanoma cells in tissue culture. Melanoma Res 1995;5:355-64.
205. Lowdell CP, Ash DV, Driver I, Brown SB. Interstitial photodynamic therapy: clinical experience with diffusing fibres in the treatment of cutaneous and subcutaneous tumours. Br J Cancer 1993;67:1398-403.
206. Grant WE, Hopper C, Speight PM, Macrobert AJ, Bown SG. Photodynamic therapy of malignant and premalignant lesions in patients with "field cancerization" of the oral cavity. J Laryngol Otol 1993;107:1140-5.
207. Gluckman JL, Portugal LG. Photodynamic therapy for cutaneous malignancies of the head and neck. Otolaryngol Clin North Am 1993;26:311-8.
208. Sperduto PW, DeLaney TF, Thomas G, Smith P, Dachowski LJ, Russo A, et al. Photodynamic therapy for chest wall recurrence in breastcancer. Int J Radiat Oncol Biol Phys 1991;21:441-6.
209. Khan SA, Dougherty TJ, Mang TS. An evaluation of photodynamic therapy in the management of cutaneous metastases of breast cancer. Eur J Cancer 1993;29A:1686-90.
210. Gregory GF, Hopper C, Fan K, Grant WE, Bown SG, Speight PM. Photodynamic therapy and lip vermilion dysplasia: a pilot study. Eur J Cancer 1995;31B:346-7.
211. Stender IM, Wulf HC. Photodynamic therapy with 5-aminolevulinic acid in the treatment of actinic cheilitis. Br J Dermatol 1996;135:454-6.
212. Silver H. Psoriasis vulgaris treated with hematoporphyrin. Arch Dermatol Syphilol 1937;36:1118-9.
213. Diezel W, Meffert H, Sonnichsen N. Therapie der Psoriasis mit Haematoporphyrin und Licht. Dermatol Monatsschr 1980; 166:793-7.
214. Berns MW, Rettenmaier M, McCullough J, Coffey J, Wile A, Berman M, et al. Response of psoriasis to red laser light (630 nm) following systemic injection of hematoporphyrin derivative. Lasers Med Surg 1984;4:73-7.
215. Emtestam L, Berglund L, Angelin B, Drummond GS, Kappas A. Tin-protoporphyrin and long wavelength ultraviolet light in treatment of psoriasis. Lancet 1989;1:1231-3.
216. McCullough JL, Weinstein GD, Berns MW. Topical hematoporphyrin derivative (HPD) photodynamic therapy for psoriasis. Laser Res Med Dent 1988;64:35-9.
217. Weinstein GD, McCullough JL, Nelson JS, Berns MW, McCormick A. Low dose Photofrin II photodynamic therapy of psoriasis [abstract]. Clin Res 1991;39:509A.
218. Hruza L, Lui H, Hruza G, McLean D, Grossman M, Kollias N, et al. Response of psoriasis to photodynamic therapy using benzoporphyrin derivative monoacid ring A. Lasers Surg Med Suppl 1995;7:43.
219. Nelson JS, Jeffes EWB, Weinstein JL, McCullough JL.Topical 5-aminolevulinic acid for the photodynamic therapy of psoriasis and actinic keratoses. Lasers Surg Med Suppl 1995;7:43.
220. Boehncke WH, Sterry W, Kaufmann R. Treatment of psoriasis by topical photodynamic therapy with polychromatic light. Lancet 1994;343:801.
221. Boehncke WH, Koenig K, Kaufmann R, Scheffold W, Pruemmer O, Sterry W. Photodynamic therapy in psoriasis: suppression of cytokine production in vitro and recording of fluorescence modification during treatment in vivo. Arch Dermatol Res 1994;286:300-3.
222. Neuner P, Charvat B, Knobler R, Urbanski A, Luger TA, Schwarz T. PUVA treatment downregulates the release of of TNF alpha, IL-1 beta and IL-8 by peripheral blood mononuclear cells. J Invest Dermatol 1992;98:505.
223. Schultz EW, Krueger AP. Inactivation of staphylococcus bacteriophage by methylene blue. Proc Soc Exp Biol Med 1930;26: 100-1.
224. Perdrau JR, Todd C. Photodynamic action of methylene blue on certain viruses. Proc R Soc B 1933;112:277-87.
225. Clifton CE. Photodynamic action of certain dyes on the inactivation of staphylococcus bacteriophage. Proc Soc Exp Biol Med 1931;28:745-6.
226. Bockstahler LE, Coohill TP, Hellman KB, Lytle CD, Roberts JE. Photodynamic therapy for herpes simplex: a critical review. Pharmacol Ther 1979;4:473-99.
227. Felber TD, Smith EB, Knox JM, Wallis C, Melnick JL. Photodynamic inactivation of herpes simplex. JAMA 1973; 223:289-92.
228. Friedrich EG Jr, Kaufman RH, Lynch PJ, Woodruff JD. Vulvar histology after neutral red photoinactivation of herpes simplex virus. Obstet Gynecol 1976;48:564-70.
229. Smetana Z, Malik Z, Orenstein A, Mendelson E, Ben-Hur E. Treatment of viral infections with 5-aminolevulinic acid and light. Lasers Surg Med 1997;21:351-8.
230. Shikowitz MJ, Galli R, Bandyopadhyay D, Hoory S. Biodistribution of indium 111-labeled dihematoporphyrin ether in papillomas and body tissues. Arch Otolaryngol Head Neck Surg 1989;115:845-7.
231. Shikowitz MJ, Steinberg BM, Abramson AL. Hematoporphyrin derivative therapy of papillomas. Arch Otolaryngol Head Neck Surg 1986;112:42-6.
232. Go PMNYH, Reed RN, Straight RC, Waner M. Laser photodynamic therapy for papilloma viral lesions. Arch Otolaryngol Head Neck Surg 1990;116:1177-80.
233. Lofgren LA, Ronn AM, Nouri M, Lee CJ, Yoo D, Steinberg BM. Efficacy of intravenous δ-aminolaevulinic acid photodynamic therapy on rabbit papillomas. Br J Cancer 1995;72:857-64.
234. Abramson AL, Shikowitz MJ, Mullooly VM, Steinberg BM, Hyman RB. Clinical effects of photodynamic therapy on recurrent laryngeal papillomas. Arch Otolaryngol Head Neck Surg 1992;118:25-9.
235. Feyh J. Photodynamic therapy of head and neck tumors. Adv Otorhinolaryngol 1995;49:53-7.
236. Stender I-M, Wulf HC. Treatment of recalcitrant verrucae by photodynamic therapy with topical application of d-aminolaevulinic acid. Clin Exp Dermatol 1996;21:390.
237. Ammann R, Hunziker T, Braathen LR. Topical photodynamic therapy in verrucae: a pilot study. Dermatology 1995;191:346-7.
238. Frank RGJ, Bos JD, van der Meulen FW, Sterenborg HJCM. Photodynamic therapy for condylomata acuminata with local application of 5-aminolevulinic acid. Genitourin Med 1996; 72:70-1.
239. Ross EV, Romero R, Kollias N, Crum C, Anderson RR. Selectivity of protoporphyrin IX fluorescence for condylomata after topical application of 5-aminolaevulinic acid: implications for photodynamic treatment. Br J Dermatol 1997;137:736-42.
240. Gaspard S, Tempete C, Werner G. Studies on photoinactivation by various phthalocyanines of a free replicating enveloped virus. J Photochem Photobiol B 1995;31:159-62.
241. North J, Neyndorff H, King D, Levy JG. Viral inactivation in blood and red cell concentrates with benzoporphyrin derivative. Blood Cells 1992;18:129-40.
242. Orenstein A, Nelson JS, Liaw L-H, Kaplan R, Kimel S, Berns MW. Photochemotherapy of hypervascular dermal lesions: a possible alternative to photothermal therapy? Lasers Surg Med 1990;10:334-43.
243. Keller GS, Doiron D, Weingarten C. Advances in laser skin surgery for vascular lesions. Arch Otolaryngol 1985;111:437-40.
244. Lin X-X, Wang W, Wu S-F, Yang C, Chang T-S.Treatment of capillary vascular malformation (port-wine stains) with photochemotherapy. Plast Reconstr Surg 1997;99:1826-30.
245. Leroy D, Deschamps P. Long-term side effects after intramuscular injection of hematoporphyrin derivative. Photodermatology 1986;3:197-9.
246. Grossman M, Wimberly J, Dwyer P, Flotte T, Anderson RR. PDT for hirsutism. Lasers Surg Med 1995;7(Suppl):44.
247. Monfrecola G, D'Anna F, Delfino M. Topical hematoporphyrin plus UVA for treatment of alopecia areata. Photodermatology 1987;4:305-6.
248. Meffert H, Gaunitz K, Gutewort T, Amlong UJ. Therapy of acne with visible light: decreased irradiation time by using a blue-light high-energy lamp. Dermatol Monatsschr 1990;176:597-603.
249. Kaye ET, Levin JA, Blank IH, Arndt KA, Anderson RR. Efficiency of opaque photoprotective agents in the visible light range. Arch Dermatol 1991;127:351-5.
250. Boyle DG, Potter WR. Photobleaching of Photofrin II as a means of eliminating skin photosensitivity. Photochem Photobiol 1987;46:997-1001.
251. Dougherty TJ, Weishaupt KR, Boyle DG. Photodynamic therapy and cancer. In: De Vita VJ, Hellman S, Rosenberg SA, editors. Principles and practices of oncology. 2nd ed. Philadelphia: JB Lippincott; 1985.
252. Webber J, Kessel D, Fromm D. Side effects and photosensitization of human tissues after aminolevulinic acid. J Surg Res 1997;68:31-7.
253. Regula J, MacRobert AJ, Gorchein A, Buonaccorsi GA, Thorpe SM, Spencer GM, et al. Photosensitization and photodynamic therapy of oesophageal, duodenal, and colorectal tumors using 5 aminolaevulinic acid induced protoporphyrin IX: a pilot study. Gut 1995;36:67-75.
254. Gorchein A, Webber R. δ-Aminolevulinic acid in plasma, cerebrospinal fluid, saliva and erythrocytes: studies in normal, uraemic and porphyric subjects. Clin Sci 1987;72:103-12.
255. McGillion FB, Thompson GG, Moore MR, Goldberg A. The passage of δ-aminolevulinic acid across the blood-brain barrier of the rat. Biochem Pharmacol 1974;23:472-4.
256. Dagg JH, Goldberg A, Lochhead A, Smith JA.The relationship of lead poisoning to acute intermittent porphyria. Q J Med 1965;34:163-75.
257. Abramson AL, Alvi A, Mullooly VM. Clinical exacerbation od systemic lupus erythematosus after photodynamic therapy of laryngotracheal papillomatosis. Lasers Surg Med 1993;13:677-9.
258. Stender I-M, Wulf HC. Koebner reaction induced by photodynamic therapy using delta-aminolevulinic acid. Acta Derm Venereol (Stockh) 1996;76:392-3.
259. Wolf P, Fink-Puches R, Reimann-Weber A, Kerl H. Development of malignant melanoma after repeated topical photodynamic therapy with 5-aminolevulinic acid at the exposed site. Dermatology 1997;194:53-4.
260. Wooten RS, Smith KC, Ahlquist DA, Muller SA, Balm RK. Prospective study of cutaneous phototoxicity after systemic hematoporphyrin derivative. Lasers Surg Med 1988;8:294-300.
261. Herrera-Ornelas L, Petrilli NJ, Mittelman A. Photodynamic therapy in patients with colorectal cancer. Cancer 1986;57:677-84.
262. Nambisan RN, Karakousis CP, Holyoke ED, Dougherty TJ. Intraoperative photodynamic therapy for retroperitoneal sarcomas. Cancer 1988;61:1248-52.
263. Biel MA. Photodynamic therapy of head and neck cancers. Semin Surg Oncol 1995;11:355-9.
264. Biel MA. Photodynamic therapy as an adjuvant intraoperative treatment of recurrent head and neck carcinomas. Arch Otolaryngol Head Neck Surg 1996;122:1261-5.
265. Biel MA. Photodynamic therapy and the treatment of head and neck cancers. J Clin Laser Med Surg 1996;14:239-44.
266. Henderson BW. Photodynamic therapy: coming of age. Photodermatology 1989;6:200-11.
267. Cowled PA, Mackenzie L, Forbes IJ. Pharmacological modulation of photodynamic therapy with hematoporphyrin derivative and light. Cancer Res 1987;47:971-4.
268. Nahabedian MY, Cohen RA, Contino MF, Terem TM, Wright WH, Berns MW, et al. Combination cytotoxic chemotherapy with cisplatin or doxorubicin and photodynamic therapy in murine tumors. J Natl Cancer Inst 1988;80:739-43.
269. Canti G, Nicolin A, Cubeddu R, Taroni P, Bandieramonte G, Valentini G. Antitumor efficacy of the combination of photodynamic therapy and chemotherapy in murine tumors. Cancer Lett 1998;125:39-44.
270. Baas P, van Geel IP, Oppelaar H, Meyer M, Beynen JH, van Zandwijk N, et al. Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study. Br J Cancer 1996;73:945-51.
271. Werning JW, Stepnick DW, Jafri A, Megerian CA, Antunez AR, Zaidi SIA. Metoclopramide enhances the effect of photodynamic therapy on xenografted human squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1995;121:783-9.
272. Cowled PA, Forbes IJ. Modification by vasoactive drugs of tumor destruction by photodynamic therapy with hematoporphyrin derivative. Br J Cancer 1989;59:904-9.
273. Mang TS, Dougherty TJ. Time and sequence dependent influence of in vivo photodynamic therapy survival by hyperthermia. Photochem Photobiol 1985;42:533-40.
274. Waldow SM, Henderson BW, Dougherty TJ. Potentiation of photodynamic therapy by heat: effect of sequence and time interval between treatments in vivo. Lasers Surg Med 1985; 5:83-94.
275. 2 distribution in tumor tissue of DS-carcinoma. Oncology 1974;30:475-84.
276. Kostron H, Schwartz MR, Miller DC, Martuza RL. The interaction of hematoporphyrin derivative, light, and ionizing radiation in a rat glioma model. Cancer 1986;57:964-70.